Clinical Trial Update: PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 2/Phase 3 study comparing PD-1 inhibitors versus PD-L1 inhibitors, each with chemotherapy with or without …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Snippet

Sponsor: N.N. Alexandrov National Cancer Centre | Conditions: Metastatic Cervical Cancer, Persistent Cervical Cancer | Phase 2, Phase 3 | Status: RECRUITING